Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01017120 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne
A Phase 3 study of Acne Vulgaris, sponsored by Stiefel, a GSK Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 742
- Enrollment target
- 18
- Study locations
NCT01017120 is a Phase 3 study of Acne Vulgaris that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 742 participants, above the 264-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (181% higher). The trial reports 18 study locations across 14 states.
The verdict
NCT01017120, a Phase 3 study of Acne Vulgaris, has completed, sponsored by Stiefel, a GSK Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 742 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.
Conditions Studied
Interventions
- DRUG Vehicle Foam
- DRUG Tazarotene Foam
Study Locations (18)
Georgia
- Atlanta Dermatology & Vein Research Center, PC - Alpharetta
- Gwinnett Clinical Research Center, Inc. - Snellville
Michigan
- Henry Ford Medical Center - Detroit
- Somerset Skin Centre - Troy
Texas
- Suzanne Bruce and Associates, PA - Houston
- Progressive Clinical Research - San Antonio
Ontario
- Lynderm Research, Inc. - Markham
- North Bay Dermatology Centre - North Bay
California
- The Laser Institute for Dermatology - Santa Monica
Florida
- FXM Research Corporation - Miami
Indiana
- Hudson Dermatology - Evansville
Kentucky
- Dermatology Specialists - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 742 participants |
| Start Date | 2009-10-01 |
| Est. Completion | 2010-11-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01017120
The ClinicalTrials.gov registry entry for NCT01017120 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 742 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 264-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (181% higher). The listed sponsor is Stiefel, a GSK Company, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Vehicle Foam is the first listed.
NCT01017120 reports 18 study locations spanning 14 distinct geographic areas - top geographies include Georgia, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT01017120 about?
NCT01017120 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne". The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.
What is the current status of trial NCT01017120?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 742 participants. The study started on 2009-10-01. Estimated completion is 2010-11-09.
What conditions does trial NCT01017120 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT01017120?
The interventions under investigation include: Vehicle Foam (DRUG), Tazarotene Foam (DRUG).
Who is sponsoring clinical trial NCT01017120?
This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01017120 being conducted?
This trial has 18 study locations across California, Florida, Georgia, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
COMPLETED · Phase 3
-
A Study of S6G5T3 in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
P3 Long Term Safety Study of Once Daily SB204 in Acne
COMPLETED · Phase 3
-
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
COMPLETED · Phase 3
-
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.